Physician profile
Daniel Ryan
NPI 1588839567
$449.15
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $431 · 2022: $18.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $151.71 | 2021-2022 | |
| Alfasigma USA, INC. | $99.17 | 2021 | |
| Amgen INC. | $88.84 | 2021 | |
| Fidia Pharma USA INC. | $20.18 | 2021 | |
| Collegium Pharmaceutical, INC. | $20.16 | 2021 | |
| Biodelivery Sciences International, INC. | $19.02 | 2021 | |
| Abbvie INC. | $18.28 | 2021 | |
| Lilly USA, LLC | $16.70 | 2021 | |
| Scilex Pharmaceuticals INC. | $15.09 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.